SynthesisSystematic reviews2012
F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.
Synthesis in Systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- SEOM clinical guideline for the management of cutaneous melanoma (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.The Cochrane database of systematic reviews · 2019Pooled it
- FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- The Impact of a Regional Community of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma.Annals of surgical oncology · 2026Article
- Differentiating lymph node status in malignant melanoma: the role of apparent diffusion coefficient ratio in diffusion-weighted MRI - a prospective diagnostic study.BMC medical imaging · 2026Article
- The Reporting and Methodological Quality of Systematic Reviews Underpinning Clinical Practice Guidelines Focused on the Management of Cutaneous Melanoma: Cross-Sectional Analysis.JMIR dermatology · 2023Article
- Whole-Body Imaging for the Primary Staging of Melanomas-A Single-Center Retrospective Study.Cancers · 2023Article
- Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment.Diagnostics (Basel, Switzerland) · 2023Review
- The Evolution of the Sentinel Node Biopsy in Melanoma.Life (Basel, Switzerland) · 2023Review
- Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.International journal of molecular sciences · 2023Review
- The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.Frontiers in oncology · 2023Article
- Article
- PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.Cancers · 2022Review
- The Role and Potential ofDiagnostics (Basel, Switzerland) · 2022Review
- Imaging findings of malignant skin tumors: radiological-pathological correlation.Insights into imaging · 2022Review
- F-18 Fluoro-2-Deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Melanoma: Normal Variants, Pitfalls, and Artifacts.Frontiers in nuclear medicine · 2022Review
- Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.Radiologic clinics of North America · 2021Review
- Melanoma With an Unknown Primary in an Asymptomatic Elderly Male With Unilateral Lymphadenopathy.Cureus · 2021Article
- CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.Abdominal radiology (New York) · 2021Review
- Positron Emission Tomography in Merkel Cell Carcinoma.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledPURPOSE: The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma. MATERIALS AND
methodsFor the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool.
resultsNo RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%.
conclusionThere is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.